Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization ; volume:80 ; number:6 ; day:19 ; month:10 ; year:2017 ; pages:1171-1178 ; date:12.2017
Cancer chemotherapy and pharmacology ; 80, Heft 6 (19.10.2017), 1171-1178, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Verheijen, R. B.
- Contributor
-
Swart, L. E.
Beijnen, J. H.
Schellens, J. H. M.
Huitema, A. D. R.
Steeghs, N.
SpringerLink (Online service)
- DOI
-
10.1007/s00280-017-3463-x
- URN
-
urn:nbn:de:1111-201801134325
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Verheijen, R. B.
- Swart, L. E.
- Beijnen, J. H.
- Schellens, J. H. M.
- Huitema, A. D. R.
- Steeghs, N.
- SpringerLink (Online service)
Other Objects (12)
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Pazopanib-induced enteritis in a patient with renal cell carcinoma
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients
Reversible Hypopigmentation with Pazopanib
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Pazopanib-induced enteritis in a patient with renal cell carcinoma
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients
Reversible Hypopigmentation with Pazopanib
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
Pazopanib-induced enteritis in a patient with renal cell carcinoma
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients
Reversible Hypopigmentation with Pazopanib
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report